APO Research
Talk to an analyst

APO RESEARCH · REPORT

Severe Asthma Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Severe Asthma Treatment Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchSevere Asthma Treatment Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Severe Asthma Treatment Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Severe Asthma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Severe Asthma Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Severe Asthma Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Severe Asthma Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Severe Asthma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Severe Asthma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Severe Asthma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Severe Asthma Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Severe Asthma Treatment market include Teva Pharmaceutical, Suzhou Connect Biopharmaceuticals, Sanofi, Novartis, Roche, GlaxoSmithKline, AstraZeneca, Regeneron Pharmaceutical and Pieris Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Severe Asthma Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Severe Asthma Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Severe Asthma Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Severe Asthma Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Severe Asthma Treatment Segment by Company

Teva Pharmaceutical

Suzhou Connect Biopharmaceuticals

Sanofi

Novartis

Roche

GlaxoSmithKline

AstraZeneca

Regeneron Pharmaceutical

Pieris Pharma

Morphosys

Biosion

Avalo Therapeutics

AB Pharma

4D Pharma plc

Severe Asthma Treatment Segment by Type

lntravenous

Oral

Subcutaneous

lnhaled

Severe Asthma Treatment Segment by Application

Teenagers

Children

Adults

Severe Asthma Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Severe Asthma Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Severe Asthma Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Severe Asthma Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Severe Asthma Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Severe Asthma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Severe Asthma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Severe Asthma Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Severe Asthma Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Severe Asthma Treatment industry.

Chapter 3: Detailed analysis of Severe Asthma Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Severe Asthma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Severe Asthma Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Severe Asthma Treatment Industry Trends Table 2. Severe Asthma Treatment Industry Drivers Table 3. Severe Asthma Treatment Industry Opportunities and Challenges Table 4. Severe Asthma Treatment Industry Restraints Table 5. Global Severe Asthma Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Severe Asthma Treatment Revenue Share by Company (2021-2026) Table 7. Global Severe Asthma Treatment Sales Volume by Company (k units) & (2021-2026) Table 8. Global Severe Asthma Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Severe Asthma Treatment Average Price (US$/unit) of Company (2021-2026) Table 10. Global Severe Asthma Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Severe Asthma Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Severe Asthma Treatment Company, Product Type & Application Table 13. Global Severe Asthma Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Severe Asthma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of lntravenous Table 18. Significant Companies of Oral Table 19. Significant Companies of Subcutaneous Table 20. Significant Companies of lnhaled Table 21. Global Severe Asthma Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Severe Asthma Treatment Sales Volume by Type (2021-2026) & (k units) Table 23. Global Severe Asthma Treatment Sales Volume by Type (2027-2032) & (k units) Table 24. Global Severe Asthma Treatment Sales Volume Share by Type (2021-2026) Table 25. Global Severe Asthma Treatment Sales Volume Share by Type (2027-2032) Table 26. Global Severe Asthma Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Severe Asthma Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Severe Asthma Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Severe Asthma Treatment Sales Value Share by Type (2021-2026) Table 30. Global Severe Asthma Treatment Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Teenagers Table 32. Significant Companies of Children Table 33. Significant Companies of Adults Table 34. Global Severe Asthma Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Severe Asthma Treatment Sales Volume by Application (2021-2026) & (k units) Table 36. Global Severe Asthma Treatment Sales Volume by Application (2027-2032) & (k units) Table 37. Global Severe Asthma Treatment Sales Volume Share by Application (2021-2026) Table 38. Global Severe Asthma Treatment Sales Volume Share by Application (2027-2032) Table 39. Global Severe Asthma Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Severe Asthma Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Severe Asthma Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Severe Asthma Treatment Sales Value Share by Application (2021-2026) Table 43. Global Severe Asthma Treatment Sales Value Share by Application (2027-2032) Table 44. Global Severe Asthma Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Severe Asthma Treatment Sales by Region (2021-2026) & (k units) Table 46. Global Severe Asthma Treatment Sales Market Share by Region (2021-2026) Table 47. Global Severe Asthma Treatment Sales by Region (2027-2032) & (k units) Table 48. Global Severe Asthma Treatment Sales Market Share by Region (2027-2032) Table 49. Global Severe Asthma Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Severe Asthma Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Severe Asthma Treatment Sales Value Share by Region (2021-2026) Table 52. Global Severe Asthma Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Severe Asthma Treatment Sales Value Share by Region (2027-2032) Table 54. Global Severe Asthma Treatment Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Severe Asthma Treatment Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Severe Asthma Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Severe Asthma Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Severe Asthma Treatment Sales by Country (2021-2026) & (k units) Table 59. Global Severe Asthma Treatment Sales Market Share by Country (2021-2026) Table 60. Global Severe Asthma Treatment Sales by Country (2027-2032) & (k units) Table 61. Global Severe Asthma Treatment Sales Market Share by Country (2027-2032) Table 62. Global Severe Asthma Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Severe Asthma Treatment Sales Value Market Share by Country (2021-2026) Table 64. Global Severe Asthma Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Severe Asthma Treatment Sales Value Market Share by Country (2027-2032) Table 66. Teva Pharmaceutical Company Information Table 67. Teva Pharmaceutical Business Overview Table 68. Teva Pharmaceutical Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Teva Pharmaceutical Severe Asthma Treatment Product Portfolio Table 70. Teva Pharmaceutical Recent Development Table 71. Suzhou Connect Biopharmaceuticals Company Information Table 72. Suzhou Connect Biopharmaceuticals Business Overview Table 73. Suzhou Connect Biopharmaceuticals Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Suzhou Connect Biopharmaceuticals Severe Asthma Treatment Product Portfolio Table 75. Suzhou Connect Biopharmaceuticals Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Sanofi Severe Asthma Treatment Product Portfolio Table 80. Sanofi Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Novartis Severe Asthma Treatment Product Portfolio Table 85. Novartis Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Roche Severe Asthma Treatment Product Portfolio Table 90. Roche Recent Development Table 91. GlaxoSmithKline Company Information Table 92. GlaxoSmithKline Business Overview Table 93. GlaxoSmithKline Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. GlaxoSmithKline Severe Asthma Treatment Product Portfolio Table 95. GlaxoSmithKline Recent Development Table 96. AstraZeneca Company Information Table 97. AstraZeneca Business Overview Table 98. AstraZeneca Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. AstraZeneca Severe Asthma Treatment Product Portfolio Table 100. AstraZeneca Recent Development Table 101. Regeneron Pharmaceutical Company Information Table 102. Regeneron Pharmaceutical Business Overview Table 103. Regeneron Pharmaceutical Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Regeneron Pharmaceutical Severe Asthma Treatment Product Portfolio Table 105. Regeneron Pharmaceutical Recent Development Table 106. Pieris Pharma Company Information Table 107. Pieris Pharma Business Overview Table 108. Pieris Pharma Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Pieris Pharma Severe Asthma Treatment Product Portfolio Table 110. Pieris Pharma Recent Development Table 111. Morphosys Company Information Table 112. Morphosys Business Overview Table 113. Morphosys Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Morphosys Severe Asthma Treatment Product Portfolio Table 115. Morphosys Recent Development Table 116. Biosion Company Information Table 117. Biosion Business Overview Table 118. Biosion Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Biosion Severe Asthma Treatment Product Portfolio Table 120. Biosion Recent Development Table 121. Avalo Therapeutics Company Information Table 122. Avalo Therapeutics Business Overview Table 123. Avalo Therapeutics Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Avalo Therapeutics Severe Asthma Treatment Product Portfolio Table 125. Avalo Therapeutics Recent Development Table 126. AB Pharma Company Information Table 127. AB Pharma Business Overview Table 128. AB Pharma Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. AB Pharma Severe Asthma Treatment Product Portfolio Table 130. AB Pharma Recent Development Table 131. 4D Pharma plc Company Information Table 132. 4D Pharma plc Business Overview Table 133. 4D Pharma plc Severe Asthma Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. 4D Pharma plc Severe Asthma Treatment Product Portfolio Table 135. 4D Pharma plc Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Severe Asthma Treatment Distributors List Table 139. Severe Asthma Treatment Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Severe Asthma Treatment Product Image Figure 2. Global Severe Asthma Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Severe Asthma Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Severe Asthma Treatment Sales (2021-2032) & (k units) Figure 5. Global Severe Asthma Treatment Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Severe Asthma Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. lntravenous Image Figure 10. Oral Image Figure 11. Subcutaneous Image Figure 12. lnhaled Image Figure 13. Global Severe Asthma Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Severe Asthma Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Severe Asthma Treatment Sales Volume Share by Type (2021-2032) Figure 16. Global Severe Asthma Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Severe Asthma Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Severe Asthma Treatment Sales Value Share by Type (2021-2032) Figure 19. Teenagers Image Figure 20. Children Image Figure 21. Adults Image Figure 22. Global Severe Asthma Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Severe Asthma Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Severe Asthma Treatment Sales Volume Share by Application (2021-2032) Figure 25. Global Severe Asthma Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Severe Asthma Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Severe Asthma Treatment Sales Value Share by Application (2021-2032) Figure 28. Global Severe Asthma Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Severe Asthma Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Severe Asthma Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Severe Asthma Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Severe Asthma Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. North America Severe Asthma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Severe Asthma Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Severe Asthma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Severe Asthma Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Severe Asthma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Severe Asthma Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. South America Severe Asthma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Severe Asthma Treatment Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Severe Asthma Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Severe Asthma Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Severe Asthma Treatment Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Severe Asthma Treatment Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • lntravenous
  • Oral
  • Subcutaneous
  • lnhaled
Applications
  • Teenagers
  • Children
  • Adults
Companies covered
  • Teva Pharmaceutical
  • Suzhou Connect Biopharmaceuticals
  • Sanofi
  • Novartis
  • Roche
  • GlaxoSmithKline
  • AstraZeneca
  • Regeneron Pharmaceutical
  • Pieris Pharma
  • Morphosys
  • Biosion
  • Avalo Therapeutics
  • AB Pharma
  • 4D Pharma plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Severe Asthma Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Severe Asthma Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Severe Asthma Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Severe Asthma Treatment Market Dynamics
  1. 2.1 Severe Asthma Treatment Industry Trends
  2. 2.2 Severe Asthma Treatment Industry Drivers
  3. 2.3 Severe Asthma Treatment Industry Opportunities and Challenges
  4. 2.4 Severe Asthma Treatment Industry Restraints
3 Severe Asthma Treatment Market by Company
  1. 3.1 Global Severe Asthma Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Severe Asthma Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Severe Asthma Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Severe Asthma Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Severe Asthma Treatment Company Ranking (2024-2026)
  6. 3.6 Global Severe Asthma Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Severe Asthma Treatment Company Product Type and Application
  8. 3.8 Global Severe Asthma Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Severe Asthma Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Severe Asthma Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Severe Asthma Treatment Market by Type
  1. 4.1 Severe Asthma Treatment Type Introduction
  2. 4.1.1 lntravenous
  3. 4.1.2 Oral
  4. 4.1.3 Subcutaneous
  5. 4.1.4 lnhaled
  6. 4.2 Global Severe Asthma Treatment Sales Volume by Type
  7. 4.2.1 Global Severe Asthma Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Severe Asthma Treatment Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Severe Asthma Treatment Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Severe Asthma Treatment Sales Value by Type
  11. 4.3.1 Global Severe Asthma Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Severe Asthma Treatment Sales Value by Type (2021-2032)
  13. 4.3.3 Global Severe Asthma Treatment Sales Value Share by Type (2021-2032)
5 Severe Asthma Treatment Market by Application
  1. 5.1 Severe Asthma Treatment Application Introduction
  2. 5.1.1 Teenagers
  3. 5.1.2 Children
  4. 5.1.3 Adults
  5. 5.2 Global Severe Asthma Treatment Sales Volume by Application
  6. 5.2.1 Global Severe Asthma Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Severe Asthma Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Severe Asthma Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Severe Asthma Treatment Sales Value by Application
  10. 5.3.1 Global Severe Asthma Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Severe Asthma Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Severe Asthma Treatment Sales Value Share by Application (2021-2032)
6 Severe Asthma Treatment Regional Sales and Value Analysis
  1. 6.1 Global Severe Asthma Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Severe Asthma Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Severe Asthma Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Severe Asthma Treatment Sales by Region (2027-2032)
  5. 6.3 Global Severe Asthma Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Severe Asthma Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Severe Asthma Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Severe Asthma Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Severe Asthma Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Severe Asthma Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Severe Asthma Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Severe Asthma Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Severe Asthma Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Severe Asthma Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Severe Asthma Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Severe Asthma Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Severe Asthma Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Severe Asthma Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Severe Asthma Treatment Sales Value Share by Country, 2025 VS 2032
7 Severe Asthma Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Severe Asthma Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Severe Asthma Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Severe Asthma Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Severe Asthma Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Severe Asthma Treatment Sales by Country (2027-2032)
  6. 7.4 Global Severe Asthma Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Severe Asthma Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Severe Asthma Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Severe Asthma Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Severe Asthma Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Severe Asthma Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Severe Asthma Treatment Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Suzhou Connect Biopharmaceuticals
  8. 8.2.1 Suzhou Connect Biopharmaceuticals Company Information
  9. 8.2.2 Suzhou Connect Biopharmaceuticals Business Overview
  10. 8.2.3 Suzhou Connect Biopharmaceuticals Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Suzhou Connect Biopharmaceuticals Severe Asthma Treatment Product Portfolio
  12. 8.2.5 Suzhou Connect Biopharmaceuticals Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Severe Asthma Treatment Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Severe Asthma Treatment Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Severe Asthma Treatment Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Severe Asthma Treatment Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Severe Asthma Treatment Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Regeneron Pharmaceutical
  44. 8.8.1 Regeneron Pharmaceutical Company Information
  45. 8.8.2 Regeneron Pharmaceutical Business Overview
  46. 8.8.3 Regeneron Pharmaceutical Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Regeneron Pharmaceutical Severe Asthma Treatment Product Portfolio
  48. 8.8.5 Regeneron Pharmaceutical Recent Developments
  49. 8.9 Pieris Pharma
  50. 8.9.1 Pieris Pharma Company Information
  51. 8.9.2 Pieris Pharma Business Overview
  52. 8.9.3 Pieris Pharma Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pieris Pharma Severe Asthma Treatment Product Portfolio
  54. 8.9.5 Pieris Pharma Recent Developments
  55. 8.10 Morphosys
  56. 8.10.1 Morphosys Company Information
  57. 8.10.2 Morphosys Business Overview
  58. 8.10.3 Morphosys Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Morphosys Severe Asthma Treatment Product Portfolio
  60. 8.10.5 Morphosys Recent Developments
  61. 8.11 Biosion
  62. 8.11.1 Biosion Company Information
  63. 8.11.2 Biosion Business Overview
  64. 8.11.3 Biosion Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Biosion Severe Asthma Treatment Product Portfolio
  66. 8.11.5 Biosion Recent Developments
  67. 8.12 Avalo Therapeutics
  68. 8.12.1 Avalo Therapeutics Company Information
  69. 8.12.2 Avalo Therapeutics Business Overview
  70. 8.12.3 Avalo Therapeutics Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Avalo Therapeutics Severe Asthma Treatment Product Portfolio
  72. 8.12.5 Avalo Therapeutics Recent Developments
  73. 8.13 AB Pharma
  74. 8.13.1 AB Pharma Company Information
  75. 8.13.2 AB Pharma Business Overview
  76. 8.13.3 AB Pharma Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AB Pharma Severe Asthma Treatment Product Portfolio
  78. 8.13.5 AB Pharma Recent Developments
  79. 8.14 4D Pharma plc
  80. 8.14.1 4D Pharma plc Company Information
  81. 8.14.2 4D Pharma plc Business Overview
  82. 8.14.3 4D Pharma plc Severe Asthma Treatment Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 4D Pharma plc Severe Asthma Treatment Product Portfolio
  84. 8.14.5 4D Pharma plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Severe Asthma Treatment Value Chain Analysis
  2. 9.1.1 Severe Asthma Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Severe Asthma Treatment Sales Mode & Process
  6. 9.2 Severe Asthma Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Severe Asthma Treatment Distributors
  9. 9.2.3 Severe Asthma Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst